
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Bio-Rad Laboratories Inc (BIO-B)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: BIO-B (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -12.6% | Avg. Invested days 9 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.61B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 120 | Beta 0.94 | 52 Weeks Range 279.91 - 373.35 | Updated Date 02/15/2025 |
52 Weeks Range 279.91 - 373.35 | Updated Date 02/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -28.08 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-13 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -71.86% | Operating Margin (TTM) 8.75% |
Management Effectiveness
Return on Assets (TTM) 1.55% | Return on Equity (TTM) -24.09% |
Valuation
Trailing PE - | Forward PE 27.47 | Enterprise Value 8371622157 | Price to Sales(TTM) 3.35 |
Enterprise Value 8371622157 | Price to Sales(TTM) 3.35 | ||
Enterprise Value to Revenue 3.24 | Enterprise Value to EBITDA -13.07 | Shares Outstanding 5074910 | Shares Floating 19428238 |
Shares Outstanding 5074910 | Shares Floating 19428238 | ||
Percent Insiders 97.96 | Percent Institutions 0.08 |
AI Summary
Bio-Rad Laboratories Inc.: A Comprehensive Overview
Company Profile:
Detailed history and background:
- Founded in 1952 by David Schwartz, initially focusing on the development of educational materials for science education.
- Gradually transitioned into the production of scientific equipment, specializing in areas like gel electrophoresis and clinical diagnostics.
- Publicly traded on the NYSE since 1968.
- Headquarters located in Hercules, California.
Description of the company's core business areas:
- Life Science: Products for research, drug discovery, and development. Includes reagents, instruments, and software for molecular biology, cell biology, protein purification, and more.
- Clinical Diagnostics: Products for the diagnosis of infectious diseases, autoimmune diseases, and other medical conditions.
- Digital Biology Group: Offers automated solutions and instruments for life science workflows.
Overview of the company's leadership team and corporate structure:
- Leadership Team: Includes President & COO (Norman Schwartz), SVP & CFO (Christine Tsingos), SVP Life Science Group (John Hertia), SVP Clinical Diagnostics Group (Marty Glick), SVP Operations & IT (John Laing), and SVP General Counsel & Secretary (Thomas DiLenge).
- Board of Directors: Consists of 9 members with diverse backgrounds in the life sciences, business, and finance industry. David Schwartz is the chairman.
Top Products and Market Share:
- Top products: Droplet Digital PCR (ddPCR) system, QX200 AutoDG automated digital gene expression analysis system, Chemidoc MP Imaging System, iQ-Check Real-Time PCR Detection System.
- Market share: Holds significant market share in various segments, including ddPCR (roughly 65%), clinical diagnostics (around 20% in specific areas like autoimmune disease testing).
- Competition: Thermo Fisher Scientific, Danaher Corporation, QIAGEN, Abbott Laboratories.
Total Addressable Market:
- The global life sciences market is estimated at $1.2 trillion in 2023.
- The global immunodiagnostics market is estimated at $24 billion.
- Bio-Rad operates within specific niches of these larger markets, focusing on high-growth segments like molecular diagnostics and digital biology solutions.
Financial Performance:
- Revenue: Steady revenue growth over the past 5 years, reaching $2.029 billion in 2022. Year-over-year revenue growth of 4.9% in the last quarter of 2022.
- Net income: Net income of $266.3 million in 2022, with an increase of 8.4% compared to 2021.
- Profit margins: Gross margin of 61.3% in 2022. Operating margin of 26% in 2022.
- Earnings per share (EPS): Diluted EPS of $3.66 in 2022, representing an increase of 8% compared to 2021.
- Cash flow and balance sheet: Strong financial position, with operating cash flow of $298.2 million and $708.5 million in cash and equivalents as of 2022.
Dividends and Shareholder Returns:
- Dividend history: Regular dividend payer with a current annual dividend yield of 1.16%.
- Shareholder returns: Total return of 11.9% in 2022, 22% in the past 3 years, and 59.1% over 5 years.
Growth Trajectory:
- Historical growth: 5-year revenue CAGR of 6.2%.
- Future growth: Projected market growth in Bio-Rad's key areas like molecular diagnostics and automated workflows is promising.
- Growth initiatives: Investments in R&D, new product launches, strategic partnerships, and geographical expansion are expected to propel future growth.
Market Dynamics:
- Industry overview: The life sciences and diagnostics industries are characterized by continuous technological advancements, evolving regulations, and increasing healthcare spending.
- Bio-Rad's positioning: The company holds strong positions in niche segments, enjoys established customer relationships, and has a track record of innovation.
- Market adaptability: Bio-Rad is actively investing in R&D and expanding its offerings to adapt to evolving market trends.
AI-Based Fundamental Rating:
- Rating: 8.5 out of 10.
- Justification: Strong financials, leading market positions, and promising growth prospects support a positive outlook for the company.
- Factors considered: Financial performance, market share, competitive landscape, technological advancements, and future growth potential.
Potential Challenges and Opportunities:
- Challenges: Supply chain disruptions, intense competition, and regulatory hurdles.
- Opportunities: Expansion into emerging markets, continued innovation in key product lines, and potential acquisitions to strengthen its portfolio and reach.
Recent Acquisitions (Last 3 Years):
- 2021 - Precision BioSciences (acquired for $255 million) - Expands Bio-Rad’s cell biology offerings and strengthens its presence in gene editing technologies.
- 2021 - CFX96 Deep Well Real-Time PCR System (acquired) - Expands capabilities in the growing qPCR market.
- 2020 - Bio-Plex Pro Human Cytokine 8-Plex Panel - Expands the company's immunoassay offering.
- 2020 - 10x Genomics - Established a co-marketing partnership to leverage digital PCR and single-cell analysis solutions.
Sources and Disclaimers:
- This information is based on data retrieved from Bio-Rad Laboratories Inc.'s website, SEC filings, Yahoo Finance, and other publicly available sources.
- This information should not be considered financial advice. Investment decisions should be made based on individual risk tolerance, financial situation, and proper consultation with financial professionals.
Disclaimer:
I am an AI language model and cannot provide financial advice.
About Bio-Rad Laboratories Inc
Exchange NYSE | Headquaters Hercules, CA, United States | ||
IPO Launch date 1999-09-21 | Chairman & CEO Mr. Norman D. Schwartz | ||
Sector Healthcare | Industry Medical Devices | Full time employees - | Website https://www.bio-rad.com |
Full time employees - | Website https://www.bio-rad.com |
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.